Tag:
Zuplenz
Latest Headlines
Latest Headlines
Incomplete plant inspections prevent Zuplenz approval
Unable to complete necessary plant inspections in India, Strativa Pharmaceuticals and Par Pharmaceuticals said today that the FDA couldn't approve the NDA for Zuplenz (ondansetron). The drug is an
